MarketPulse

KRAS inhibitor

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Cogent Biosciences, Inc.

Cogent Biosciences Showcases Dual Pipeline Advances at AACR 2026 Meeting

Cogent Biosciences highlights preclinical data for KRAS and HER2 inhibitors at AACR 2026, with IND submission planned for CGT1263.
COGTIND submissionAACR Annual Meeting
BenzingaBenzinga··Bamboo Works

Jacobio Pharma Eyes 2026 Profitability on AstraZeneca Deal and Cancer Drug Sales

Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.
AZNprofitabilitylicensing agreement